Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | IDH2 | P48735 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394700 | 0.85 | HRH4 (0.62) | HRH4HRH3 | |
| SCHEMBL4397049 | 0.84 | IDH2 (0.56) | HRH4CTSCMAPTBRAFIDH2 | |
| SCHEMBL4397043 | 0.82 | HRH4 (0.52) | HRH4HRH3 | |
| SCHEMBL27738437 | 0.82 | AURKA (0.60) | HRH4HRH3 | |
| SCHEMBL2165477 | 0.80 | HRH4 (0.67) | HRH4HRH3 | |
| SCHEMBL27717385 | 0.79 | HRH4 (0.67) | HRH4HRH3 | |
| SCHEMBL4396293 | 0.79 | HRH4 (0.54) | HRH4HRH3MAPTIDH2LMNA | |
| SCHEMBL4390422 | 0.78 | HRH4 (0.64) | HRH4HRH3 | |
| SCHEMBL4395534 | 0.78 | IDH2 (0.58) | HRH4CTSCHRH3MAPTIDH2 | |
| SCHEMBL4401425 | 0.78 | HRH4 (0.57) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
| EP-1928862-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR ACTIVITY | Palau Pharma, S.A. (ES) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007031529-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR ACTIVITY | PALAU PHARMA, S.A. (ES) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | HRH4 1/4885USP2 4140/4885SMN1; SMN2 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.